| atezolizumab based treatment | avelumab based treatment | nivolumab based treatment | anti-PD-(L)1 |
| atezolizumab alone | avelumab alone | nivolumab alone | Tislelizumab |
| mNSCLC - L2 - all population 5 | | | | |
Comparator:
vs docetaxel;
Risk of bias:
low;
some concerns;
high;
NA;